First Wave Biopharma, headquartered in Boca Raton, Florida, develops nonsystemic therapies for gastrointestinal diseases and went public in October 2016. Its key programs include latiglutenase, capeserod, and adrulipase.
ENTO has been in the news recently: IDBS conducted a survey of 856 BioPharma professionals, with 77% expressing satisfaction with its platform aimed at improving data quality and research efficiency. Additionally, multiple law firms are filing class action lawsuits against Zenas BioPharma for allegedly misleading investors during its IPO on September 13, 2024.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
